Kronos Bio, Inc. (KRON)
NASDAQ: KRON · Real-Time Price · USD
0.955
+0.024 (2.61%)
Sep 26, 2024, 4:00 PM EDT - Market closed
Kronos Bio Revenue
Kronos Bio had revenue of $2.69M in the quarter ending June 30, 2024, with 44.21% growth. This brings the company's revenue in the last twelve months to $8.41M, up 172.76% year-over-year. In the year 2023, Kronos Bio had annual revenue of $6.29M.
Revenue (ttm)
$8.41M
Revenue Growth
+172.76%
P/S Ratio
6.53
Revenue / Employee
$133,524
Employees
63
Market Cap
57.56M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Theratechnologies | 82.57M |
SHL Telemedicine | 57.08M |
Enzo Biochem | 33.34M |
Qilian International Holding Group | 29.87M |
SCYNEXIS | 9.67M |
VolitionRx | 976.52K |
CollPlant Biotechnologies | 689.00K |
Actinium Pharmaceuticals | 81.00K |
KRON News
- 1 day ago - Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy - GlobeNewsWire
- 3 days ago - Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer - GlobeNewsWire
- 23 days ago - Kronos Bio Announces Participation in Medical and Investor Conferences in September - GlobeNewsWire
- 2 months ago - Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer - GlobeNewsWire
- 4 months ago - Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 4 months ago - Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events - GlobeNewsWire
- 4 months ago - Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer - GlobeNewsWire
- 5 months ago - Kronos Bio Reports First-Quarter 2024 Financial Results - GlobeNewsWire